Depression
GABA
Glutamate
Insomnia
Magnetic Resonance Spectroscopy
Sleep
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
02
10
2019
revised:
13
04
2020
accepted:
10
05
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
16
2
2021
Statut:
ppublish
Résumé
Both Major Depressive Disorder (MDD) and Primary Insomnia (PI) have been linked to deficiencies in cortical γ-aminobutyric acid (GABA) and glutamate (Glu) thus suggesting a shared neurobiological link between these two conditions. The extent to which comorbid insomnia contributes to GABAergic or glutamatergic deficiencies in MDD remains unclear. We used single-voxel proton magnetic resonance spectroscopy ( MDD subjects exhibited a 15% decrease in Glu/Cr in the dACC compared to HC. Within the MDD group, there was a trend inverse correlation between dACC Glu/Cr and anhedonia ratings. We observed no significant association between measures of sleep quality with dACC Glu/Cr in those with MDD. The protocol and data interpretation would have been enhanced by the recruitment of MDD subjects with a broader range of affect severity and a more comprehensive assessment of clinical features. These findings support the role of cortical glutamatergic mechanisms in the pathophysiology of MDD. Insomnia severity did not further contribute to the relative deficiency of glutamatergic measures in MDD.
Sections du résumé
BACKGROUND
Both Major Depressive Disorder (MDD) and Primary Insomnia (PI) have been linked to deficiencies in cortical γ-aminobutyric acid (GABA) and glutamate (Glu) thus suggesting a shared neurobiological link between these two conditions. The extent to which comorbid insomnia contributes to GABAergic or glutamatergic deficiencies in MDD remains unclear.
METHODS
We used single-voxel proton magnetic resonance spectroscopy (
RESULTS
MDD subjects exhibited a 15% decrease in Glu/Cr in the dACC compared to HC. Within the MDD group, there was a trend inverse correlation between dACC Glu/Cr and anhedonia ratings. We observed no significant association between measures of sleep quality with dACC Glu/Cr in those with MDD.
LIMITATIONS
The protocol and data interpretation would have been enhanced by the recruitment of MDD subjects with a broader range of affect severity and a more comprehensive assessment of clinical features.
CONCLUSIONS
These findings support the role of cortical glutamatergic mechanisms in the pathophysiology of MDD. Insomnia severity did not further contribute to the relative deficiency of glutamatergic measures in MDD.
Identifiants
pubmed: 32663996
pii: S0165-0327(19)32673-4
doi: 10.1016/j.jad.2020.05.026
pmc: PMC10662933
mid: NIHMS1601895
pii:
doi:
Substances chimiques
Glutamic Acid
3KX376GY7L
gamma-Aminobutyric Acid
56-12-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
624-631Subventions
Organisme : NIMH NIH HHS
ID : R01 MH095792
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest Dr. John Winkelman reports acting as a consultant for Flex Pharma, Merck, and Otsuka; receiving honoraria from Cambridge University Press and UpToDate; and receiving research support from Luitpold Pharmaceuticals, the RLS Foundation, UCB Biosciences, and Xenoport. All other authors declare that they have no conflicts of interest.
Références
Mol Psychiatry. 2013 Mar;18(3):268-70
pubmed: 22565784
Psychol Med. 2003 Oct;33(7):1277-84
pubmed: 14580081
Arch Gen Psychiatry. 2009 May;66(5):478-86
pubmed: 19414707
Biol Psychiatry. 2000 Feb 15;47(4):305-13
pubmed: 10686265
Psychiatry Clin Neurosci. 2014 May;68(5):357-64
pubmed: 24393367
Magn Reson Med. 1993 Dec;30(6):672-9
pubmed: 8139448
Biol Psychiatry. 2010 Nov 1;68(9):785-94
pubmed: 20728076
Psychiatry Res. 2003 Apr 1;122(3):185-92
pubmed: 12694892
NMR Biomed. 1998 Oct;11(6):266-72
pubmed: 9802468
J Affect Disord. 2019 Apr 1;248:166-174
pubmed: 30735853
Nature. 2005 Oct 27;437(7063):1257-63
pubmed: 16251950
Arch Gen Psychiatry. 2012 Feb;69(2):139-49
pubmed: 21969419
Neuroscience. 2002;111(2):231-9
pubmed: 11983310
Sleep. 2014 May 01;37(5):893-900
pubmed: 24790267
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Hum Brain Mapp. 2016 Sep;37(9):3337-52
pubmed: 27145016
Biol Psychiatry. 2017 May 15;81(10):886-897
pubmed: 27449797
NMR Biomed. 2001 Jun;14(4):260-4
pubmed: 11410943
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
Sleep. 2008 Nov;31(11):1499-506
pubmed: 19014069
Sleep. 2007 Nov;30(11):1547-54
pubmed: 18041487
Arch Gen Psychiatry. 2007 Feb;64(2):193-200
pubmed: 17283286
Am J Psychiatry. 2008 Dec;165(12):1543-50
pubmed: 18765482
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
PLoS One. 2016 Jun 10;11(6):e0156771
pubmed: 27285311
Arch Gen Psychiatry. 2004 Jul;61(7):705-13
pubmed: 15237082
Dialogues Clin Neurosci. 2008;10(3):329-36
pubmed: 18979946
Front Syst Neurosci. 2010 Jul 15;4:
pubmed: 20700385
Sleep. 2017 Nov 1;40(11):
pubmed: 28958033
Psychiatry Res. 2014 Sep 30;223(3):253-60
pubmed: 24973815
J Affect Disord. 2003 Sep;76(1-3):255-9
pubmed: 12943956
Neuropsychopharmacology. 2012 May;37(6):1548-57
pubmed: 22318195
J Affect Disord. 2007 Nov;103(1-3):77-82
pubmed: 17321595
Neurosci Biobehav Rev. 2012 Jan;36(1):198-205
pubmed: 21672551
Curr Opin Neurobiol. 2017 Jun;44:101-109
pubmed: 28433001
Arch Gen Psychiatry. 1999 Nov;56(11):1043-7
pubmed: 10565505
Am J Epidemiol. 1997 Jul 15;146(2):105-14
pubmed: 9230772
Mol Psychiatry. 2018 Apr;23(4):801-811
pubmed: 29532791
Mol Psychiatry. 2019 Jul;24(7):952-964
pubmed: 30315224
Biol Psychiatry. 2009 May 1;65(9):792-800
pubmed: 19058788
Int J Neuropsychopharmacol. 2008 Mar;11(2):255-60
pubmed: 17625025
Psychiatry Res Neuroimaging. 2017 Nov 30;269:9-16
pubmed: 28892734
Front Psychiatry. 2017 Jul 11;8:123
pubmed: 28744229
J Psychosom Res. 1993 Jan;37(1):19-32
pubmed: 8421257
Sleep. 2012 Jun 01;35(6):807-14
pubmed: 22654200